This datacard is using Medicaid State Drug Utilization data to see market trends in reimbursement for Lipitor.lip
Purpose: reimbursement, market research

Entities include: drugs

To learn more about karmadata or Medicaid State Drug Utilization data, you can reach out directly to

This datacard uses Medicare Part B data to identify top physicians or locales for specific outpatient procedures.

Purpose: clinical operations, market research

Entities: physicians, outpatient procedures

For more information on karmadata or Medicare Part B data, be sure to sign up for a weekly webinar: or reach out directly to

In case you didn’t notice, there is a new feature in Sponsor Finder.  On the left side of the page, just under “Reset” and “Search”, you can select “Find sponsor management contacts“. 

Sponsor Contacts Search

Although you can find contacts through companies that are returned in a Sponsor Finder search, this section allows you to search by title, name, location, or level across ALL sponsors.  There are over 500K management contacts (with email and phone numbers), which are all provided through ZoomInfo. Many of our users are currently using it to get lists of contacts together for projects, email campaigns, sales pipelines, etc.

If you would like a refresher or training of the system, you can always sign up for our weekly webinars at

This datacard uses the NIH Grant RePORTER data to identify leading research institutions, particularly pre-clinical.

Purpose: clinical operations, market research

Entities: organizations, investigators, diseases, drugs

This card uses the Sunshine Act Data [Pharma Payments to US Physicians] to identify top researchers with strong ties to pharma.

#datashows sunshine

Entities: Sponsors and Physicians

Purpose: clinical operations, competitive intelligence


This card uses the Medicare Part D Database.

14_5M_claims_related_to_10_359_Cities___karmadataEntities include: physicians, drugs

Purpose: market research, clinical operations

This datacard uses the Medicare Part D Database to identify top prescribers and top to prescribing geographies of drugs.


Entities include: physicians, drugs

Purpose: market research, clinical operations


This datacard uses the FDA Orphan Drugs Database to identify top players in the orphan space.

199_FDA_Orphan_Drug_Designations_related_to_139_Organizations___karmadataEntities include: Sponsors, diseases, and drugs

Purpose: business intelligence, market research, and business development.


Today, we take the time to thank and support all clinical research professionals on International Clinical Trials’ Day.  Many would think that this day was just picked by some organization to celebrate the success of clinical trials throughout the years.  But, in fact May 20th is the date when James Lind started his famous trial on how to treat scurvy.  We have come a long way since having a clinical trial to treat scurvy. Lind paved the way for clinical discovery and finding new means of treatment.

One of the main obstacles with clinical trials today is recruitment.  Organizations are having a difficult time getting the bodies they need for the trials they are conducting.  Without participation these trials can not have an effective outcome, or even worse, no outcome at all.  What many do not know is that for some, participation may be a form of treatment.  For example, for breast cancer patients clinical trials are no longer just an extra thing to do.  Instead, a trial may be their best option for breast cancer treatment.  This can also be said for many other health concerns out there.

If you check out the data card below, you are able to see the number of clinical trials that are currently recruiting across the United States:19_9K_Clinical_Trials_related_to_51_Site_States___karmadataI was shocked when I saw how many thousands of trials fall under this status, especially when it is only focusing in on the U.S.  There are endless amount of patients across the globe who are waiting for new therapies and new drugs to emerge into the market.  There is a need for more and more clinical trials, but we also need the patients to take part in these trials.  I believe that if we focus on the patient side by providing them with better information to understand clinical trials, then more will be able to take the initiative to participate.  I have seen an increase in the number of trials even over this past year alone.  I look forward to seeing what this year has in store for the clinical trials industry.